The company is looking to secure Neuspera System approval for use in treating UUI. Credit: Neuspera Medical.

Neuspera Medical has closed its Series D funding round, securing $23m to advance its Implantable Sacral Neuromodulation (SNM) System towards US Food and Drug Administration (FDA) premarket approval.

Vertex Ventures HC and Treo Ventures spearheaded the investment, with additional funds from Windham Venture Partners, Action Potential Venture Capital, Olympus Innovation Ventures, and another strategic investor.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The Neuspera implantable system is designed to manage urinary urge incontinence (UUI), a distressing symptom of overactive bladder (OAB).

Neuspera’s technology is intended to provide a discreet and minimally invasive solution to address this issue.

The device features an ultra-miniaturised pulse generator connected to an electrode array. It is designed to be implanted within the sacral foramen, without the discomfort of a protruding implant.

This design also negates the tunnelling and a separate pocket for an implanted battery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Neuspera Medical CEO Steffen Hovard said: “We’re excited to bring new partners on board as we approach the next significant milestone of submitting the Neuspera System for regulatory approval.

“The confidence and conviction of our new and existing investors, like Olympus Innovation Ventures, demonstrates the strength and potential of our platform technology.”

Currently, the company’s device has FDA clearance for the treatment of chronic pain of peripheral nerve origin.

Neuspera Medical is now focusing on obtaining approval for its use in treating UUI.

Olympus chief strategy officer and Olympus Innovation Ventures president Gabriela Kaynor said: “As a partner of choice for innovators in urology, we are thrilled to invest in the Neuspera team as they bring the Neuspera System through FDA approval and to the market.

“Based on critical unmet market need and patient demand, changes in society guidelines, and positive feedback from patients and physicians in clinical trials, we are excited to invest in the Neuspera team as they build their innovative Neuspera System for OAB.”